| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $0 | — | -100.0% |
| R&D Expense | $730K | — | +1927.8% |
| SG&A Expense | $2.5M | — | +65.0% |
| Operating Income | -$3.2M | — | -120.2% |
| Net Income | -$3.2M | — | -122.3% |
| EPS (Basic) | -$0.76 | — | -35.7% |
| EPS (Diluted) | -$0.76 | — | -35.7% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $2.8M | -12.9% | -22.4% |
| Accounts Receivable | $0 | -100.0% | -100.0% |
| Current Assets | $3.1M | -33.4% | -31.3% |
| Total Assets | $8.5M | -14.8% | -13.6% |
| Current Liabilities | $1.7M | +90.4% | +60.6% |
| Stockholders' Equity | $6.8M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$1.2M | — | -21.5% |
| Capital Expenditures | $66K | — | — |
| Investing Cash Flow | -$66K | — | — |
| Financing Cash Flow | $825K | — | -40.0% |
| Free Cash Flow | -$1.2M | — | -28.3% |
| -22.7% |